Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data – NEW YORK, November 21, 2024 – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud…
